HOUSTON, Sept. 28, 2020 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that management will participate in two upcoming virtual conferences.
Conference Details:Jefferies Cell Therapy Virtual Summit
Date/Time: Monday, October 5, 2020 at 11:30 a.m. EDT
Format: Fireside chat2020 Virtual Cell & Gene Meeting on the Mesa
Date: Monday, October 12, 2020 – Friday, October 16, 2020
Format: Prerecorded company presentation will be available for registered attendees to view on-demand throughout the entirety of the conference. Please visit www.meetingonthemesa.com for full information including registration.A live webcast of the fireside chat at the Jefferies Cell Therapy Summit may be accessed from the Events & Presentation section of the Bellicum website. An archived version of the Jefferies fireside chat will be available for replay following the event.About Bellicum PharmaceuticalsBellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T and CAR-NK cell therapies. Bellicum’s GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com.Source: Bellicum PharmaceuticalsInvestors:Robert H. Uhl
Managing Director
Westwicke ICR
858-356-5932
Robert.uhl@westwicke.com
Bay Street News